<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cg Oncology, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/cg-oncology-inc-common-stock</link>
    <description>Latest news and press releases for Cg Oncology, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 May 2026 20:15:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cg-oncology-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683554e978dffbe2df0e9188.webp</url>
      <title>Cg Oncology, Inc.</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock</link>
    </image>
    <item>
      <title>CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncologys-presence-at-american-urological-association-aua-annual-meeting-underscores-its-strong-commitment-to-nmibc</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncologys-presence-at-american-urological-association-aua-annual-meeting-underscores-its-strong-commitment-to-nmibc</guid>
      <pubDate>Mon, 11 May 2026 20:15:00 GMT</pubDate>
      <description>-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 T</description>
    </item>
    <item>
      <title>CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-updates</guid>
      <pubDate>Fri, 08 May 2026 12:30:00 GMT</pubDate>
      <description>Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026Well-positioned to deliver on key milestones with approximately</description>
    </item>
    <item>
      <title>CG Oncology to Present at Upcoming Investor Conferences in May</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-to-present-at-upcoming-investor-conferences-in-may</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-to-present-at-upcoming-investor-conferences-in-may</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 GMT</pubDate>
      <description>DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman &amp; Chief Executive Officer, and Ambaw Bellete, President &amp; Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026Date: Tuesday, May 12, 2026Presentation Tim</description>
    </item>
    <item>
      <title>CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-2025-year-end-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-2025-year-end-financial-results-and-provides-business-updates</guid>
      <pubDate>Fri, 27 Feb 2026 13:30:00 GMT</pubDate>
      <description>PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029 IRVINE, Calif., Feb. 27, 2026 (GLOB</description>
    </item>
    <item>
      <title>CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman &amp; Chief Executive Officer, and</description>
    </item>
    <item>
      <title>Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/oncolytics-biotechr-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-yujun-wu-to-lead-biostatistics</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/oncolytics-biotechr-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-yujun-wu-to-lead-biostatistics</guid>
      <pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
      <description>Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancersSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biost</description>
    </item>
    <item>
      <title>CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-provides-updated-timeline-133000613</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-provides-updated-timeline-133000613</guid>
      <pubDate>Fri, 09 Jan 2026 13:30:00 GMT</pubDate>
      <description>- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial compar</description>
    </item>
    <item>
      <title>CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and</description>
    </item>
    <item>
      <title>SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/suo-ctc-and-cg-oncology-announce-second-annual-non-muscle-invasive-bladder-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/suo-ctc-and-cg-oncology-announce-second-annual-non-muscle-invasive-bladder-cancer</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of</description>
    </item>
    <item>
      <title>New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/new-cretostimogene-grenadenorepvec-data-highlight-its-potential-become-backbone</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/new-cretostimogene-grenadenorepvec-data-highlight-its-potential-become-backbone</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort PCORE-008</description>
    </item>
    <item>
      <title>CG Oncology Announces New Board Member and Board Transition</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-announces-new-board-member-and-board-transition-2025-11-26</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-announces-new-board-member-and-board-transition-2025-11-26</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology,</description>
    </item>
    <item>
      <title>CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-present-results-cretostimogene-grenadenorepvec-society-urologic-oncology</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-present-results-cretostimogene-grenadenorepvec-society-urologic-oncology</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in</description>
    </item>
    <item>
      <title>CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-third-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-third-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
      <description>Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle</description>
    </item>
    <item>
      <title>CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-continues-demonstrate-best-disease-durability-and-tolerability-bond-003</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-continues-demonstrate-best-disease-durability-and-tolerability-bond-003</guid>
      <pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
      <description>- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer</description>
    </item>
    <item>
      <title>CG Oncology Completes Enrollment in PIVOT-006</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-completes-enrollment-pivot-006-2025-09-03</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-completes-enrollment-pivot-006-2025-09-03</guid>
      <pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
      <description>– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3</description>
    </item>
    <item>
      <title>CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncologys-executive-leadership-participate-upcoming-investor-conferences-2025-08</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncologys-executive-leadership-participate-upcoming-investor-conferences-2025-08</guid>
      <pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
      <description>IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and</description>
    </item>
    <item>
      <title>CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
      <description>- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American</description>
    </item>
    <item>
      <title>Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/delaware-superior-court-jury-issues-unanimous-verdict-cg-oncology-owes-no-future</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/delaware-superior-court-jury-issues-unanimous-verdict-cg-oncology-owes-no-future</guid>
      <pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
      <description>IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and</description>
    </item>
    <item>
      <title>Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/lustgarten-foundation-appoints-arthur-kuan-ms-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/lustgarten-foundation-appoints-arthur-kuan-ms-to-board-of-directors</guid>
      <pubDate>Tue, 01 Jul 2025 18:30:00 GMT</pubDate>
      <description>The Lustgarten Foundation, the world&apos;s largest private funder of pancreatic cancer research, today announced the appointment of Arthur Kuan, MS, to its Board of Directors. Mr. Kuan is the Chairman and Chief Executive Officer of CG Oncology, a clinical-stage biotechnology company pioneering oncolytic immunotherapies for patients with urologic cancers.</description>
    </item>
    <item>
      <title>CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
      <link>https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/cg-oncology-inc-common-stock/news/cg-oncology-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025</guid>
      <pubDate>Thu, 05 Jun 2025 04:00:00 GMT</pubDate>
      <description>IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and</description>
    </item>
  </channel>
</rss>